Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01276067 · ClinicalTrials.gov registry record · Phase 1

Bioequivalence Study of Donepezil Hydrochloride 10 mg Tablets Under Fasting Conditions

A Phase 1 study, sponsored by Ranbaxy Laboratories Limited.

Completed
Registry status
Phase 1
Development phase
32
Enrollment target

NCT01276067: Completed Phase 1 study, sponsored by Ranbaxy Laboratories Limited.

NCT01276067 is a Phase 1 study that has completed, run by Ranbaxy Laboratories Limited. The registered enrollment target is 32 participants. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01276067, a Phase 1 study, has completed, sponsored by Ranbaxy Laboratories Limited.

COMPLETED
Registry status
Phase 1
Development phase
32 participants
Enrollment target

Study Summary

This open label, balanced, randomized, two-treatment, two-period, two-sequence, single dose crossover study was conducted to compare the relative bioavailability of equal doses of the test and reference products under fasted conditions.

Interventions

  • DRUG Donepezil

Trial Details

FieldValue
Enrollment Target 32 participants
Start Date 2009-10
Est. Completion 2009-12
Phase Phase 1

Sponsor

Ranbaxy Laboratories Limited

44 total trials

What the Registry Record Tells You About NCT01276067

The ClinicalTrials.gov registry entry for NCT01276067 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ranbaxy Laboratories Limited, which has 44 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which Donepezil is the first listed.

NCT01276067 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT01276067 about?

NCT01276067 is a clinical study titled "Bioequivalence Study of Donepezil Hydrochloride 10 mg Tablets Under Fasting Conditions". This open label, balanced, randomized, two-treatment, two-period, two-sequence, single dose crossover study was conducted to compare the relative bioavailability of equal doses of the test and reference products under fasted conditions.

What is the current status of trial NCT01276067?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 32 participants. The study started on 2009-10. Estimated completion is 2009-12.

What interventions are being tested in trial NCT01276067?

The interventions under investigation include: Donepezil (DRUG).

Who is sponsoring clinical trial NCT01276067?

This trial is sponsored by Ranbaxy Laboratories Limited, which has 44 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.